Please login to the form below
Quetiapine
This page shows the latest Quetiapine news and features for those working in and with pharma, biotech and healthcare.
AZ expects return to growth this year after 2017 decline
to $2.6bn, although the cumulative effect of patent expiries - which also affect antipsychotic Seroquel XR (quetiapine) and gastrointestinal drug Nexium (esomeprazole) - are starting to dissipate.
Latest news
-
AZ CEO says company’s renaissance is on track
for cholesterol drug Crestor (rosuvastatin) and antipsychotic Seroquel XR (quetiapine).
-
Lundbeck and Otsuka's Rexulti set for August launch in US
aripiprazole that have activating side effects - such as agitation and insomnia - and sedating drugs such as quetiapine.
-
Patent cliff losses set to cost pharma $65bn by 2019
GlobalData analyst Adam Dion said: “AZ, CNS segment has been bleeding sales as a result of the company losing its patent on Seroquel (quetiapine), a treatment for bipolar disorder.
-
Abilify Maintena launches in Europe
Zyprexa (olanzapine) and AstraZeneca's Seroquel (quetiapine) - now available generically.
-
Setback for Roche as schizophrenia candidate fails studies
The schizophrenia market has been shrinking in recent years as massively successful antipsychotic medicines such as Lilly's Zyprexa (olanzapine), AstraZeneca/Astellas' Seroquel (quetiapine) and Bristol-Myers Squibb/Otsuka Pharmaceutical's
More from news
Approximately 2 fully matching, plus 43 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Roche’s Polivy recommended by NICE for lymphoma therapy
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- ASH 2022: bad blood but big advances
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- Eli Lilly announces $450m investment in US manufacturing site
- GSK’s Benlysta given orphan drug status by FDA for systemic sclerosis
- AstraZeneca’s Imfinzi plus chemotherapy approved by MHRA for biliary tract cancer
- ICR calls for improved biomarker cancer tests to help personalise treatment
- EIT Health marks World Cancer Day with €6m pledge for new healthcare delivery models
- World Cancer Day: encouraging men to put their health first
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Strategic behaviour
- Omnichannel communications in Medical Affairs: closing the gap between aspiration and reality
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- Meeting healthcare’s rising challenges
- EU outlines measures to mitigate antibiotic shortage across Europe
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- Sanofi/Regeneron’s Dupixent recommended by CHMP for atopic dermatitis in children
PMHub
COUCH Health
We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...
Latest intelligence
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
- Strategic behaviour
- Strong strategising depends on your colleagues’ behaviour...
- Pharmaceutical Marketing Strategies For The Digital Age
- In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...
